Literature DB >> 23238720

Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.

Nathalie Dehorter1, Natalia Lozovaya, B Julius Mdzomba, François J Michel, Catherine Lopez, Vera Tsintsadze, Timur Tsintsadze, Michael Klinkenberg, Suzanna Gispert, Georg Auburger, Constance Hammond.   

Abstract

Cellular electrophysiological signatures of Parkinson's disease described in the pharmacological 6-hydroxydopamine (6-OHDA) animal models of Parkinson's disease include spontaneous repetitive giant GABAergic currents in a subpopulation of striatal medium spiny neurons (MSNs), and spontaneous rhythmic bursts of spikes generated by subthalamic nucleus (STN) neurons. We investigated whether similar signatures are present in Pink1(-/-) mice, a genetic rodent model of the PARK6 variant of Parkinson's disease. Although 9- to 24-month-old Pink1(-/-) mice show reduced striatal dopamine content and release, and impaired spontaneous locomotion, the relevance of this model to Parkinson's disease has been questioned because mesencephalic dopaminergic neurons do not degenerate during the mouse lifespan. We show that 75% of the MSNs of 5- to 7-month-old Pink1(-/-) mice exhibit giant GABAergic currents, occurring either singly or in bursts (at 40 Hz), rather than the low-frequency (2 Hz), low-amplitude, tonic GABAergic drive common to wild-type MSNs of the same age. STN neurons from 5- to 7-month-old Pink1(-/-) mice spontaneously generated bursts of spikes instead of the control tonic drive. Chronic kainic acid lesion of the STN or chronic levodopa treatment reliably suppressed the giant GABAergic currents of MSNs after 1 month and replaced them with the control tonic activity. The similarity between the in vitro resting states of Pink1 MSNs and those of fully dopamine (DA)-depleted MSNs of 6-OHDA-treated mice, together with the beneficial effect of levodopa treatment, strongly suggest that dysfunction of mesencephalic dopaminergic neurons in Pink1(-/-) mice is more severe than expected. The beneficial effect of the STN lesion also suggests that pathological STN activity strongly influences striatal networks in Pink1(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238720      PMCID: PMC6621724          DOI: 10.1523/JNEUROSCI.2474-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  33 in total

1.  A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus.

Authors:  D Plenz; S T Kital
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

2.  Distribution of spontaneous currents along the somato-dendritic axis of rat hippocampal CA1 pyramidal neurons.

Authors:  R Cossart; J C Hirsch; R C Cannon; C Dinoncourt; H V Wheal; Y Ben-Ari; M Esclapez; C Bernard
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Preservation of the direct and indirect pathways in an in vitro preparation of the mouse basal ganglia.

Authors:  C Beurrier; Y Ben-Ari; C Hammond
Journal:  Neuroscience       Date:  2006-03-31       Impact factor: 3.590

4.  Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.

Authors:  K R Kessler; N Hamscho; B Morales; C Menzel; F Barrero; F Vives; S Gispert; G Auburger
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

Review 5.  Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease.

Authors:  A Benazzouz; B Piallat; Z G Ni; A Koudsie; P Pollak; A L Benabid
Journal:  Cell Transplant       Date:  2000 Mar-Apr       Impact factor: 4.064

6.  Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  J Physiol       Date:  2006-04-13       Impact factor: 5.182

Review 7.  Lesion therapy for Parkinson's disease and other movement disorders: update and controversies.

Authors:  Michael S Okun; Jerrold L Vitek
Journal:  Mov Disord       Date:  2004-04       Impact factor: 10.338

8.  Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families.

Authors:  A R Bentivoglio; P Cortelli; E M Valente; T Ialongo; A Ferraris; A Elia; P Montagna; A Albanese
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

9.  Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.

Authors:  D Centonze; P Gubellini; S Rossi; B Picconi; A Pisani; G Bernardi; P Calabresi; C Baunez
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 10.  Pathological synchronization in Parkinson's disease: networks, models and treatments.

Authors:  Constance Hammond; Hagai Bergman; Peter Brown
Journal:  Trends Neurosci       Date:  2007-05-25       Impact factor: 13.837

View more
  6 in total

1.  Early hypersynchrony in juvenile PINK1(-)/(-) motor cortex is rescued by antidromic stimulation.

Authors:  Romain Carron; Anton Filipchuk; Romain Nardou; Abhinav Singh; Francois J Michel; Mark D Humphries; Constance Hammond
Journal:  Front Syst Neurosci       Date:  2014-05-21

2.  GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.

Authors:  N Lozovaya; S Eftekhari; R Cloarec; L A Gouty-Colomer; A Dufour; B Riffault; M Billon-Grand; A Pons-Bennaceur; N Oumar; N Burnashev; Y Ben-Ari; C Hammond
Journal:  Nat Commun       Date:  2018-04-12       Impact factor: 14.919

3.  Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.

Authors:  Rose B Creed; Rosalinda C Roberts; Charlene B Farmer; Lori L McMahon; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2020-12-30       Impact factor: 5.996

4.  Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures.

Authors:  Yehezkel Ben-Ari; Philippe Damier; Eric Lemonnier
Journal:  Front Cell Neurosci       Date:  2016-04-14       Impact factor: 5.505

5.  Abnormal Development of Glutamatergic Synapses Afferent to Dopaminergic Neurons of the Pink1(-/-) Mouse Model of Parkinson's Disease.

Authors:  Edouard Pearlstein; François J Michel; Laurène Save; Diana C Ferrari; Constance Hammond
Journal:  Front Cell Neurosci       Date:  2016-06-23       Impact factor: 5.505

6.  Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.

Authors:  Sylvia Torres-Odio; Jana Key; Hans-Hermann Hoepken; Júlia Canet-Pons; Lucie Valek; Bastian Roller; Michael Walter; Blas Morales-Gordo; David Meierhofer; Patrick N Harter; Michel Mittelbronn; Irmgard Tegeder; Suzana Gispert; Georg Auburger
Journal:  J Neuroinflammation       Date:  2017-08-02       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.